Every Form 4 that Waldencast plc (WALD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow WALD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WALD filings page.
Waldencast plc (WALD) reported an insider-related purchase of Class A ordinary shares linked to director and ten-percent owner Cristiano Souza. On August 28, 2026, Zeno Investment Master Fund, for which Souza is an indirect controller, purchased 335,000 Class A shares at $1.5094 per share from Waldencast Ventures LP, bringing its indirectly held position reported for Souza to 12,587,580 shares. Souza disclaims beneficial ownership of the fund’s holdings except to the extent of his pecuniary interest.
Waldencast plc reported that CEO Michel Brousset returned 264,294 restricted stock units to the company in a disposition to the issuer at $2.00 per unit, leaving 0 units from this award. The repurchase was tied to the sale of its Obagi Medical dermatological skincare and aesthetics business, after which he transitioned to lead Obagi Medical.
Waldencast plc reported that Chief Growth Officer and director Hind Sebti disposed of 193,816 Restricted Stock Units, each representing one Class A ordinary share, in a disposition to the issuer at $2.00 per RSU. The RSUs were purchased by Waldencast in connection with the completion of the sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026, when Sebti transitioned to lead Obagi Medical. These RSUs came from an October 30, 2024 grant of 290,723 RSUs that had been scheduled to vest in three annual tranches, and following this transaction no RSUs from this grant remain reported for Sebti.
Waldencast plc’s Chief Financial Officer, Manuel Manfredi, reported the accelerated vesting and settlement of 79,289 restricted stock units (RSUs) into the same number of Class A ordinary shares on July 30, 2026. This occurred upon completion of Waldencast’s sale of its Obagi Medical dermatological skincare and aesthetics business, after which he transitioned to lead Obagi Medical. Following the settlement, he directly holds 118,933 Class A ordinary shares. A prior grant of 118,933 RSUs dated October 30, 2024 had originally been scheduled to vest in three annual tranches.